Caris Life Sciences, a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the launch of Caris ChromoSeq™, a Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay designed to support the comprehensive clinical genomic evaluation of myeloid malignancies. The test is intended for use in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), as well as in patients with suspected myeloid malignancies characterized by unexplained cytopenia persisting for more than four months, where other potential causes have been reasonably excluded.

Myeloid malignancies are among the most genetically complex cancers, often requiring multiple tests to identify clinically relevant mutations, structural variants and chromosomal abnormalities. This fragmented approach can delay critical treatment decisions and miss detection of important genomic alterations used for diagnosis and risk stratification.

Caris ChromoSeq can replace the multiple test protocols of the myeloid diagnostic workflow, complementing the clinician’s overall clinical and pathological evaluation. Building on this foundation, the test delivers approximately 250x read depth across the genome with 40 million transcriptome reads, enabling enhanced genomic resolution from a bone marrow aspirate or peripheral blood collection. Results are synthesized into a single, easy‑to‑interpret, actionable report to support confident, timely clinical decision‑making, with an expected seven-day turnaround time.

“The Caris ChromoSeq launch provides an unprecedented amount of genomic and transcriptomic data per patient, enabling a complete diagnostic evaluation in a single test. Never before have patients and physicians had access to a technology with the depth and breadth provided by Caris ChromoSeq,” said Matthew Oberley, MD, PhD, Senior Vice President, Chief Clinical Officer and Pathologist-in-Chief at Caris. “This launch reflects our commitment to delivering a single, integrated genomic solution for patients with hematological cancers that fits into real‑world clinical workflows and provides results fast enough to inform patient care.”

The launch of Caris ChromoSeq underscores Caris Life Sciences’ ongoing focus on advancing precision medicine through innovative molecular profiling technologies that simplify complexity and support clinicians across the cancer care continuum.

Source – PR Newswire